Insider Selling: Xeris Biopharma (NASDAQ:XERS) Director Sells $91,350.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Director John Johnson sold 15,000 shares of the stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total value of $91,350.00. Following the transaction, the director directly owned 683,083 shares of the company’s stock, valued at approximately $4,159,975.47. The trade was a 2.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Price Performance

Shares of Xeris Biopharma stock opened at $6.18 on Monday. The stock has a 50 day moving average of $6.10 and a 200 day moving average of $6.59. Xeris Biopharma Holdings, Inc. has a 12 month low of $4.30 and a 12 month high of $10.08. The firm has a market cap of $1.07 billion, a PE ratio of 103.00 and a beta of 0.78. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.01 EPS for the quarter. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.The company had revenue of $83.13 million during the quarter, compared to analyst estimates of $79.83 million. On average, research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its position in Xeris Biopharma by 13.8% during the fourth quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares during the period. Geode Capital Management LLC raised its holdings in shares of Xeris Biopharma by 3.3% in the fourth quarter. Geode Capital Management LLC now owns 4,275,989 shares of the company’s stock worth $33,571,000 after buying an additional 135,815 shares during the period. State Street Corp raised its holdings in shares of Xeris Biopharma by 10.1% in the fourth quarter. State Street Corp now owns 4,116,924 shares of the company’s stock worth $32,318,000 after buying an additional 378,595 shares during the period. Qube Research & Technologies Ltd raised its holdings in shares of Xeris Biopharma by 6.0% in the third quarter. Qube Research & Technologies Ltd now owns 3,274,834 shares of the company’s stock worth $26,657,000 after buying an additional 185,063 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in shares of Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after buying an additional 1,199,435 shares during the period. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have issued reports on XERS. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, May 11th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a research report on Monday, March 2nd. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.